Tomm34-KO Mouse
一般名
Tomm34-KO
製品ID
S-KO-12135
背景情報
C57BL/6JCya
系統ID
KOCMP-67145-Tomm34-B6J-VA
状況
このマウス系統を論文で使用する場合は、「Tomm34-KO Mouse（カタログ番号S-KO-12135）はサイアジェンから購入しました。」と引用してください。
製品タイプ
年齢
遺伝子型
性別
数量
標準的な配送方法では、少なくとも3匹のヘテロ接合体キャリアを保証しています。ホモ接合体キャリアや指定された性別の個体の繁殖サービスも利用可能です。
基本情報
系統名
Tomm34-KO
系統ID
KOCMP-67145-Tomm34-B6J-VA
遺伝子名
製品ID
S-KO-12135
遺伝子別名
TOM34, 2610100K07Rik
遺伝子別名
C57BL/6JCya
NCBI ID
修正
Conventional knockout
染色体
Chr 2
表現型
アプリケーション
--
さらに
系統詳細
EnsemblトランスクリプトID
ENSMUST00000018466
NCBIトランスクリプトID
NM_025996
ターゲット領域
Exon 2
有効領域の大きさ
~1.6 kb
遺伝子研究の概要
TOMM34, the 34-kDa translocase of the outer mitochondrial membrane, is a co-chaperone of Hsp70 and Hsp90. It is part of the cytosolic complex involved in mitochondrial protein import. It has been associated with pathways like oxidative phosphorylation, citric acid cycle, and purine and amino acid metabolism, as well as NOTCH -, MAPK -, and STAT3-signaling [8].
TOMM34 has been found to be highly expressed in many cancers such as colon [1], oral squamous cell carcinoma (OSCC) [2,6], epithelial ovarian cancer [4], urothelial carcinoma of the bladder [5], and early invasive breast cancer [9]. In colon cancer, its high expression correlates with immune cell infiltration and worse prognosis [1]. In OSCC, it promotes cell proliferation, migration, invasion, and modulates mitochondrial function [2]. In COVID-19 and influenza, viral induction of TOMM34 is positively correlated with hyperinflammation, as it recruits TRAF6 to facilitate NF-κB activation [3]. In hepatocellular carcinoma, it is upregulated in response to metformin-induced metabolic stress, interacting with ATP5B to preserve F1FO-ATPase activity and promote tumor metastasis [7].
In conclusion, TOMM34 plays crucial roles in maintaining mitochondrial function, cell proliferation, and immune-related processes. Its overexpression in various cancers and association with poor prognosis highlight its potential as a biomarker and therapeutic target. In severe viral infections, its role in hyperinflammation also makes it an important target for immune intervention strategies.
References:
1. Li, Zhigui, Yang, Hongzhao, Liu, Jianbo, Li, Li, Wang, Xiaodong. 2023. TOMM34 serves as a candidate therapeutic target associated with immune cell infiltration in colon cancer. In Frontiers in oncology, 13, 947364. doi:10.3389/fonc.2023.947364. https://pubmed.ncbi.nlm.nih.gov/36845719/
2. Huang, Yunyi, Chen, Zhipei, Chen, Xuanyi, Chen, Xiaohua, Xu, Meng. 2022. TOMM34 promotes cell proliferation, migration, and invasion of OSCC and modulates mitochondrial function. In Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology, 52, 47-55. doi:10.1111/jop.13382. https://pubmed.ncbi.nlm.nih.gov/36367442/
3. Shi, Qiwen, Zhang, Pengfei, Hu, Qingtao, Zhu, Wenting, Qi, Nan. 2024. Role of TOMM34 on NF-κB activation-related hyperinflammation in severely ill patients with COVID-19 and influenza. In EBioMedicine, 108, 105343. doi:10.1016/j.ebiom.2024.105343. https://pubmed.ncbi.nlm.nih.gov/39276680/
4. Muller, Petr, Coates, Philip J, Nenutil, Rudolf, Brychtova, Veronika, Vojtesek, Borivoj. 2019. Tomm34 is commonly expressed in epithelial ovarian cancer and associates with tumour type and high FIGO stage. In Journal of ovarian research, 12, 30. doi:10.1186/s13048-019-0498-0. https://pubmed.ncbi.nlm.nih.gov/30917858/
5. Ahmed, Mohamed A H, Ali, Mohamed Hassan, Abbas, Hashem Hafez, Elatrash, Gamal Ali, Foda, Abd AlRahman Mohammad. 2018. Expression of TOMM34 and Its Clinicopathological Correlations in Urothelial Carcinoma of the Bladder. In Pathology oncology research : POR, 26, 411-418. doi:10.1007/s12253-018-0524-3. https://pubmed.ncbi.nlm.nih.gov/30382527/
6. Cai, Min, Tan, Rukeng, Huang, Yunyi, Guo, Kaixin, Xu, Meng. 2021. High Expression of Tomm34 and Its Correlations With Clinicopathology in Oral Squamous Cell Carcinoma. In Pathology oncology research : POR, 27, 641042. doi:10.3389/pore.2021.641042. https://pubmed.ncbi.nlm.nih.gov/34257607/
7. Jin, Ping, Jiang, Jingwen, Zhou, Li, Wei, Yuquan, Huang, Canhua. 2022. Disrupting metformin adaptation of liver cancer cells by targeting the TOMM34/ATP5B axis. In EMBO molecular medicine, 14, e16082. doi:10.15252/emmm.202216082. https://pubmed.ncbi.nlm.nih.gov/36321555/
8. Poverennaya, Ekaterina V, Pyatnitskiy, Mikhail A, Dolgalev, Georgii V, Kim, Yan S, Ponomarenko, Elena A. 2023. Exploiting Multi-Omics Profiling and Systems Biology to Investigate Functions of TOMM34. In Biology, 12, . doi:10.3390/biology12020198. https://pubmed.ncbi.nlm.nih.gov/36829477/
9. Aleskandarany, Mohammed A, Negm, Ola H, Rakha, Emad A, Tighe, Patrick J, Ellis, Ian O. 2012. TOMM34 expression in early invasive breast cancer: a biomarker associated with poor outcome. In Breast cancer research and treatment, 136, 419-27. doi:10.1007/s10549-012-2249-4. https://pubmed.ncbi.nlm.nih.gov/23053644/
品質管理基準
精子検査
凍結前の精子濃度を測定し、精子の生存能力の判定します。
凍結後の精子では、各バッチから1本の凍結保存された精子を選び出し、体外受精に使用します。
環境基準:
SPF対応地域:
グローバル由来:
Cyagenお問い合わせ
カスタムの動物モデルに関するご相談は、下記のフォームにご記入いただき、ご連絡いただくか見積もりをご依頼ください。
Cyagenはお客様のプライバシーを大変重視しています。当社の最新の製品や情報をお届けしたいと思っています。お客様の設定をご確認ください。
これらの配信はいつでも解除できます。配信停止方法およびデータ保護の詳細は プライバシーポリシー をご確認ください。
以下のボタンをクリックすることで、このフォームにご入力いただいた個人情報をCyagenが保存・処理し、ご要望のコンテンツを提供することに同意されたことになります。